Abstract
Background: RET fusions are found in an increasing number of undifferentiated pediatric sarcomas, with many tumors occurring in the infantile fibrosarcoma spectrum. Vepafestinib (TAS0953/HM06) is a brain-penetrant 2nd generation RET-selective inhibitor that is also effective against RET solvent front (G810) and gatekeeper (V804) mutations. We evaluated the brain penetrability and efficacy of vepafestinib in preclinical sarcomas models with RET fusion.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
